Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
Lynch RC, Ujjani CS, Poh C, Warren EH, Smith SD, Shadman M, Till B, Raghunathan VM, Alig S, Alizadeh AA, Gulhane A, Chen DL, Tseng Y, Coye H, Shelby M, Ottemiller S, Keo S, Verni K, Du H, Vandermeer J, Gaston A, Rasmussen H, Martin P, Marzbani E, Voutsinas J, Gopal AK. Lynch RC, et al. Among authors: alizadeh aa. Blood. 2023 May 25;141(21):2576-2586. doi: 10.1182/blood.2022019254. Blood. 2023. PMID: 36913694 Free PMC article. Clinical Trial.
Self-antigen recognition by follicular lymphoma B-cell receptors.
Sachen KL, Strohman MJ, Singletary J, Alizadeh AA, Kattah NH, Lossos C, Mellins ED, Levy S, Levy R. Sachen KL, et al. Among authors: alizadeh aa. Blood. 2012 Nov 15;120(20):4182-90. doi: 10.1182/blood-2012-05-427534. Epub 2012 Sep 28. Blood. 2012. PMID: 23024238 Free PMC article.
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.
Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R. Myklebust JH, et al. Among authors: alizadeh aa. Blood. 2013 Feb 21;121(8):1367-76. doi: 10.1182/blood-2012-04-421826. Epub 2013 Jan 7. Blood. 2013. PMID: 23297127 Free PMC article.
Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.
Alig S, Jurinovic V, Shahrokh Esfahani M, Haebe S, Passerini V, Hellmuth JC, Gaitzsch E, Keay W, Tahiri N, Zoellner A, Rosenwald A, Klapper W, Stein H, Feller A, Ott G, Staiger AM, Horn H, Hansmann ML, Pott C, Unterhalt M, Schmidt C, Dreyling M, Alizadeh AA, Hiddemann W, Hoster E, Weigert O. Alig S, et al. Among authors: alizadeh aa. Blood Adv. 2020 Sep 22;4(18):4451-4462. doi: 10.1182/bloodadvances.2020002546. Blood Adv. 2020. PMID: 32941649 Free PMC article. Clinical Trial.
Molecular Monitoring of Lymphomas.
Schroers-Martin JG, Alig S, Garofalo A, Tessoulin B, Sugio T, Alizadeh AA. Schroers-Martin JG, et al. Among authors: alizadeh aa. Annu Rev Pathol. 2023 Jan 24;18:149-180. doi: 10.1146/annurev-pathol-050520-044652. Epub 2022 Sep 21. Annu Rev Pathol. 2023. PMID: 36130071 Free article. Review.
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. Cherng HJ, et al. Among authors: alizadeh aa. Blood Adv. 2023 Apr 11;7(7):1137-1145. doi: 10.1182/bloodadvances.2022008174. Blood Adv. 2023. PMID: 36375046 Free PMC article. Clinical Trial.
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
Lynch RC, Poh C, Ujjani CS, Warren EH, Smith SD, Shadman M, Morris K, Lee S, Rasmussen H, Ottemiller S, Shelby M, Keo S, Verni K, Kurtz DM, Alizadeh AA, Chabon JJ, Hogan GJ, Schulz A, Gooley T, Voutsinas JM, Gopal AK. Lynch RC, et al. Among authors: alizadeh aa. Blood Adv. 2023 Jun 13;7(11):2449-2458. doi: 10.1182/bloodadvances.2022009145. Blood Adv. 2023. PMID: 36521030 Free PMC article. Clinical Trial.
197 results